Possible ‘Best-in-Class’ Alzheimer’s Drug Candidate Offers ‘Disruptive’ Potential

Source: Streetwise Reports   09/20/2017 André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm’s coverage universe. Mackie Research Capital Corp. . . . → Read More: Possible ‘Best-in-Class’ Alzheimer’s Drug Candidate Offers ‘Disruptive’ Potential Similar Articles: U.S. Energy Company Offers ‘Considerable Upside’ Post Acquisition Biotech with Alzheimer’s Focus Makes Progress on Several Fronts The ProMIS of an Alzheimer’s Cure